Huntington National Bank Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Huntington National Bank raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 94.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,748 shares of the medical device company’s stock after purchasing an additional 1,335 shares during the quarter. Huntington National Bank’s holdings in DexCom were worth $214,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Public Sector Pension Investment Board lifted its position in shares of DexCom by 5.9% during the third quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock worth $1,196,000 after purchasing an additional 1,000 shares in the last quarter. Captrust Financial Advisors lifted its holdings in DexCom by 4.6% in the 3rd quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock worth $1,545,000 after buying an additional 1,022 shares in the last quarter. Benjamin Edwards Inc. acquired a new position in DexCom in the 3rd quarter worth $652,000. Jacobs Levy Equity Management Inc. boosted its position in DexCom by 660.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 34,609 shares of the medical device company’s stock valued at $2,320,000 after buying an additional 30,058 shares during the last quarter. Finally, Investment Management Corp of Ontario grew its stake in shares of DexCom by 51.8% during the third quarter. Investment Management Corp of Ontario now owns 13,194 shares of the medical device company’s stock valued at $885,000 after acquiring an additional 4,500 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Finally, Cfra Research raised shares of DexCom to a “hold” rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

Shares of DXCM opened at $59.83 on Friday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $141.99. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a fifty day moving average price of $80.14 and a 200 day moving average price of $76.92. The company has a market cap of $23.46 billion, a P/E ratio of 41.84, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.